While Jefferies analysts predict Cohance Lifesciences is poised to achieve the highest growth rate among Indian firms, Sai Life Sciences is their top pick in the sector.
As part of a licensing deal, the CDMO will produce and supply nucleic acid monomers and modified oligonucleotides to expand RNA therapeutics development.
